• Arthritis
    • Arthritis Kols
    • Paul Peter Tak

      Paul Peter Tak

      Amsterdam Rheumatology & Immunology Center (ARC), Department of Rheumatology & Clinical Immunology, 1007 MB Amsterdam, The Netherlands;, d.c.anang@amsterdamumc.nl, (D.C.A.);, ...



      KOL Resume for Paul Peter Tak


      Amsterdam Rheumatology & Immunology Center (ARC), Department of Rheumatology & Clinical Immunology, 1007 MB Amsterdam, The Netherlands;, (D.C.A.);, (T.H.R.);, (J.S.H.);, (B.v.K.);, (N.S.);, (D.M.G.);, (P.P.T.);, (N.d.V.)

      Candel Therapeutics, Needham, MA 02494, USA

      GlaxoSmithKline, Stevenage, Royaume-Uni

      Department of Internal Medicine, Cambridge University, Cambridge CB2 0QQ, UK


      Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands

      R&D GlaxoSmithKline, Stevenage, United Kingdom

      Candel Therapeutics, Needham, MA

      Multimorbidity Steering Group, Strategic Priorities Fund, Swindon, UK

      Present address: Ghent University, Ghent, Belgium


      Department of Medicine, Cambridge University, Cambridge, United Kingdom

      Rheumatology, Ghent University, 9000 Ghent, Belgium

      Kintai Therapeutics, Cambridge, MA 02140, USA

      GlaxoSmithKline, Stevenage, UK


      Cambridge University, Cambridge, United Kingdom

      Department of Clinical Immunology & Rheumatology, Academic Medical Centre, Amsterdam University Medical Centre, Amsterdam, Netherlands

      GlaxoSmithKline, Stevenage, Hertfordshire, UK

      Ghent University, Ghent, Belgium


      Department of Clinical immunology and Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam University Medical Centre, Amsterdam, The Netherlands

      GlaxoSmithKline, Stevenage

      Present address: University of Cambridge, Cambridge, UK


      GlaxoSmithKline Research & Development, Stevenage, United Kingdom

      Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

      University of Ghent, Ghent, Belgium

      GSK Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, UK


      Arthrogen B.V., Amsterdam, the Netherlands

      GlaxoSmithKline Medicines Research Centre, SG1 2NY, Stevenage, UK

      Clinical Immunology and Rheumatology Department.



      Paul Peter Tak: Influence Statistics

      Sample of concepts for which Paul Peter Tak is among the top experts in the world.
      Concept World rank
      responders prospective cohort #1
      arthritis subjects #1
      inflammation arthroscopy #1
      criteria draft criteria #1
      positive mast cells #1
      rheumatoid patients expression #1
      arthritis female humans #1
      immunoregulatory balance #1
      cd304 pdcs #1
      infections aes #1
      sections svuh #1
      rheumatoid arthritis concept #1
      responders treatment #1
      2×1000 #1
      week rituximab treatment #1
      intimal lining layer #1
      amc svuh #1
      patients parvovirus b19 #1
      ngf rheumatoid cells #1
      patients post escape #1
      monoclonal rheumatoid blymphocytes #1
      study human macrophages #1
      negative routine histology #1
      potential delivery route #1
      tls tissues #1
      treatment ccr2 #1
      work antitnf therapy #1
      at‐risk phase #1
      frbeta folate antagonists #1
      asymptomatic synovitis #1
      immunization citrullinated cii #1
      metabolic peptide #1
      analyse synovial biopsies #1
      peripheral spondylarthritis #1
      lnscs earliest phases #1
      myelomonocytic arthritis #1
      mrp1 lef #1
      subclone abundancy #1
      raavlacz #1
      patients longstanding #1
      synovial tissue fls #1
      synovial tissue stage #1
      mϕs patients #1
      8 draft #1
      synovial lymphocyte aggregates #1
      sat0240 #1
      effects il6 production #1
      cd135 axis #1
      arthroscopy samples #1


      Prominent publications by Paul Peter Tak

      KOL-Index: 20277

      BACKGROUND: Sirukumab, a human monoclonal antibody that selectively binds to the interleukin-6 cytokine with high affinity, is under development for the treatment of rheumatoid arthritis and other diseases. We aimed to assess the efficacy and safety of sirukumab for rheumatoid arthritis in a phase 3 study (SIRROUND-T).

      METHODS: We did a randomised, double-blind, placebo-controlled, parallel-group, multicentre study at 183 hospitals and private rheumatology clinics in 20 countries ...

      Known for Sirukumab Patients | Rheumatoid Arthritis | 2 Weeks | Monoclonal Antibodies | Phase 3 Study
      KOL-Index: 18685

      OBJECTIVE: To investigate how antibodies against anti-tumour necrosis factor (anti-TNF) agents influence response after switching from infliximab to adalimumab in rheumatoid arthritis (RA).

      METHODS: This cohort study consisted of 235 patients with RA, all treated with adalimumab. At baseline 52 patients (22%) had been previously treated with infliximab ('switchers'), and 183 (78%) were anti-TNF naive. Disease activity (using the 28-joint count Disease Activity Score (DAS28)) and presence ...

      Known for Adalimumab Antibodies | Patients Anti | Necrosis Factor | Response Infliximab | Illness Treatment Outcome
      KOL-Index: 17819

      BACKGROUND: Synovial tissue (ST) from end stage destructive rheumatoid arthritis (RA) and arthroscopic biopsies obtained during active inflammation might exhibit different characteristics.

      OBJECTIVE: To define the cell infiltrate and the expression of proinflammatory cytokines, angiogenic factors, and matrix metalloproteinases (MMPs) in ST selected at arthroscopy compared with that from end stage RA.

      METHODS: Synovial biopsy specimens were obtained from the actively inflamed knee joints ...

      Known for Proinflammatory Cytokines | Matrix Metalloproteinases | Cell Infiltrate | Myelomonocytic Arthritis | Synovial Biopsies
      KOL-Index: 15782

      OBJECTIVE: To evaluate the efficacy and safety of secukinumab, a fully human, anti-interleukin (IL)-17A monoclonal antibody, in patients with psoriatic arthritis (PsA).

      METHODS: 42 patients with active PsA fulfilling ClASsification for Psoriatic ARthritis (CASPAR) criteria were randomly assigned (2:1) to receive two intravenous secukinumab doses (10 mg/kg; n=28) or placebo (n=14) 3 weeks apart. The primary endpoint was the proportion of American College of Rheumatology (ACR) 20 responses ...

      Known for Psoriatic Arthritis | Placebo Week | Monoclonal Antibodies | Primary Endpoint | Safety Secukinumab
      KOL-Index: 15663

      OBJECTIVE: To evaluate the safety and efficacy of ocrelizumab plus methotrexate (MTX) or leflunomide (LEF) in patients with active rheumatoid arthritis (RA) and an inadequate response to tumor necrosis factor α inhibitors.

      METHODS: This was a multicenter randomized, double-blind, placebo-controlled, parallel-group study that continued over 48 weeks. Patients receiving stable doses of MTX or LEF were randomized to receive 2 infusions of placebo (n = 277), ocrelizumab 200 mg (n = 278), or ...

      Known for Inadequate Response | Ocrelizumab Patients | Rheumatoid Arthritis | 48 Weeks Placebo | Necrosis Factor
      KOL-Index: 15475

      BACKGROUND: A substantial proportion of patients with rheumatoid arthritis (RA) do not respond, or lose initial response, to adalimumab treatment. One explanation for non-response is that patients develop anti-adalimumab antibodies.

      OBJECTIVES: To evaluate the incidence of formation of antibody against adalimumab and the association with serum adalimumab concentrations and clinical response.

      METHODS: In a cohort of 121 consecutive patients with RA treated with adalimumab, serum ...

      Known for Adalimumab Antibodies | Rheumatoid Arthritis | 28 Weeks | Substantial Proportion | Initial Response
      KOL-Index: 15159

      BACKGROUND: Chemokine receptors and chemokines have a crucial role in leucocyte recruitment into inflamed tissue.

      OBJECTIVE: To examine the expression of an extensive number of chemokines and receptors in a unique bank of paired samples of synovial tissue (ST) and peripheral blood (PB) from patients with different forms of arthritis to assist in identifying suitable targets for therapeutic intervention.

      METHODS: Synovial biopsy specimens were obtained from 23 patients with rheumatoid ...

      Known for Reactive Arthritis | Synovial Tissue | Chemokine Receptor | Peripheral Blood | Ccr1 Ccr5
      KOL-Index: 15155

      OBJECTIVE: To determine if treatment with a B cell-targeted therapy can inhibit the progression of structural joint damage in patients with rheumatoid arthritis (RA), exhibiting an inadequate response to tumour necrosis factor (TNF) inhibitors.

      METHODS: In this phase III study, patients with an inadequate response to a TNF inhibitor and receiving methotrexate were randomised to rituximab or placebo. Radiographs were obtained at baseline, week 24 and week 56 after randomisation. Patients ...

      Known for Inadequate Response | Structural Joint Damage | Rituximab Patients | Monoclonal Antibodies | Necrosis Factor
      KOL-Index: 15046

      OBJECTIVE: Bacteria are considered to be important in the pathogenesis of several forms of arthritis. The goal of this study was to apply the 16S ribosomal RNA (rRNA)-polymerase chain reaction method for the detection of bacterial DNA in synovial fluid (SF) and synovial tissue (ST) from inflamed joints.

      METHODS: Samples from 5 patients with septic arthritis and from 7 with osteoarthritis or arthritis secondary to joint trauma were used as controls. Samples from 6 patients with ...

      Known for Bacterial Dna | Joint Samples | Undifferentiated Arthritis | 16s Ribosomal | Polymerase Chain
      KOL-Index: 14194

      OBJECTIVE: In approximately 25% of synovial tissues from rheumatoid arthritis (RA) patients, infiltrates of T cells, B cells, and follicular dendritic cells (FDCs) are spatially organized into structures resembling lymph nodes with germinal centers. The remainder of the tissues lack FDCs and show either a diffuse or an aggregated T cell and B cell infiltrate. To gain more insight into this specific disease process, we sought to identify the genes expressed in RA tissues with ectopic ...

      Known for Lymphoid Neogenesis | Arthritis Synovial | Cells Dendritic Cells | Increased Expression | Lymph Nodes
      KOL-Index: 14068

      OBJECTIVE: The objective of this exploratory study was to evaluate the effects and costs of a 6-month course of tumour necrosis factor (TNF) inhibitors on work ability, quality of life, and fatigue in patients with rheumatoid arthritis (RA).

      METHODS: In this prospective single-arm intervention study 59 consecutive patients of working age with established RA were recruited from an outpatient clinic in Amsterdam, the Netherlands. All patients received fortnightly subcutaneous injections of ...

      Known for Rheumatoid Arthritis | Work Ability | Quality Life | Monoclonal Antibodies | Fatigue Patients
      KOL-Index: 13896

      Psoriasis and psoriatic arthritis are inflammatory diseases that respond well to anti-tumour necrosis factor-alpha therapy. To evaluate the effects of anti-tumour necrosis factor-alpha treatment on expression of adhesion molecules and angiogenesis in psoriatic lesional skin and synovial tissue, we performed a prospective single-centre study with infliximab therapy combined with stable methotrexate therapy. Eleven patients with both active psoriasis and psoriatic arthritis received ...

      Known for Psoriatic Skin | Infliximab Therapy | Adhesion Molecules | Monoclonal Arthritis | Blood Vessels
      KOL-Index: 13830

      BACKGROUND: The synovial tissue is a primary target of many inflammatory arthropathies, including psoriatic arthritis (PsA). Identification of proinflammatory molecules in the synovium may help to identify potentially therapeutic targets.

      OBJECTIVE: To investigate extensively the features of cell infiltration and expression of mediators of inflammation and joint destruction in the synovium of patients with PsA compared with patients with rheumatoid arthritis matched for disease duration ...

      Known for Psoriatic Arthritis | Patients Psa | Synovial Inflammation | Joint Destruction | Cell Infiltrate
      KOL-Index: 13746

      OBJECTIVE: To investigate the relationship between serum trough infliximab levels and clinical response to infliximab treatment in patients with rheumatoid arthritis (RA).

      METHODS: Disease activity and serum trough infliximab levels before and 2, 6, and 14 weeks after initiation of infliximab treatment at a dose of 3 mg/kg in a cohort of 105 patients with RA were assessed. Serum trough infliximab levels in responders and non-responders were compared. Additionally, the clinical responses ...

      Known for Infliximab Treatment | Serum Trough | Rheumatoid Arthritis | 14 Weeks | Responders Patients

      Key People For Rheumatoid Arthritis

      Top KOLs in the world
      Paul Emery
      rheumatoid arthritis ankylosing spondylitis radiographic progression
      Josef Sebastian Smolen
      rheumatoid arthritis systemic lupus erythematosus radiographic progression
      James F Fries
      rheumatoid arthritis physical function systemic lupus erythematosus
      John Turner Sharp
      rheumatoid arthritis radiographic progression joint space width
      Frederick J Wolfe
      rheumatoid arthritis work disability rheumatic diseases
      Matthew H Liang
      rheumatoid arthritis systemic lupus erythematosus lyme disease

      Paul Peter Tak:Expert Impact

      Concepts for whichPaul Peter Takhas direct influence:Rheumatoid arthritis,  Synovial tissue,  Psoriatic arthritis,  Patients rheumatoid arthritis,  Arthritis rheumatoid,  Monoclonal antibodies,  Synovial inflammation,  Rheumatoid arthritis patients.

      Paul Peter Tak:KOL impact

      Concepts related to the work of other authors for whichfor which Paul Peter Tak has influence:Rheumatoid arthritis,  Autoimmune diseases,  Gene expression,  Systemic lupus erythematosus,  Necrosis factor,  Monoclonal antibodies,  Synovial tissue.



      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Amsterdam Rheumatology & Immunology Center (ARC), Department of Rheumatology & Clinical Immunology, 1007 MB Amsterdam, The Netherlands;, d.c.anang@amsterdamumc.nl, (D.C.A.);, ramwadhdoebe@gmail.com, (T.H.R.);, jhaehnlein@hotmail.com, (J.S.H.);, b.van

    Download on the App StoreGet it on Google Play

    Copyright © 2023 - KOL means Key Opinion Leaders .

    KOL does not provide medical advice, diagnosis or treatment.